A multi-omics analysis of advanced triple-negative breast cancer identifies predictors to chemo-immunotherapy and on-treatment dynamics
Take-home: A multi-cohort study in advanced triple-negative #BreastCancer identifies a transcriptomic signature that stratifies progression-free survival following chemo-immunotherapy. Immune-enriched tumors with organized lymphoid architecture were associated with better outcomes, while fibrotic and angiogenic microenvironments, often with PI3K alterations, were linked to poorer outcomes. Early progression involved fibrovascular remodeling, macrophage expansion, and immunosuppressive signaling, highlighting coordinated microenvironmental reprogramming as a potential mechanism of immune checkpoint inhibitor resistance.
About this highlight
A multi-omics analysis of advanced triple-negative breast cancer identifies predictors to chemo-immunotherapy and on-treatment dynamics
Nicolaas Van Renne, Elisa Agostinetto, Andrea Joaquín García, Marie Morfouace, Marcin Możejko, Zoë Denis, Sophie Déglise, Bernd Bodenmiller, Henoch S. Hong, David Venet, Marcela Carausu, Robin Liechti, Stéphanie Tissot, Sylvie Rusakiewicz, Mattia Rediti, Xavier Catteau, Daniel Schulz, Delphine Loirat, Daniel Herrero Saboya, Philippe Aftimos, Matteo Benelli, Angel L. Guerrero-Zotano, Andrea Gombos, Hans Wildiers, Jip Van Dinter, Ariane Sickinghe, Nicolas Penel, Jean-Charles Goeminne, Júlio Oliveira, Birute Brasiuniene, Emanuela Romano, Justin M. Balko, Marleen Kok, Ewa Szczurek, Christos Sotiriou, Laurence Buisseret. CellPress
- Type
- Publication pick
- Topic
- Breast
